Lyell Immunopharma, Inc.
LYEL
$13.95
$0.211.53%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 100.00% | -66.67% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 100.00% | -66.67% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | 100.00% | -66.67% | |||
| SG&A Expenses | 0.22% | -9.99% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | 7.23% | -42.45% | |||
| Total Operating Expenses | 6.95% | -28.01% | |||
| Operating Income | -6.95% | 28.01% | |||
| Income Before Tax | -85.30% | 82.84% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -85.30% | 82.84% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -85.30% | 82.84% | |||
| EBIT | -6.95% | 28.01% | |||
| EBITDA | -7.60% | 29.03% | |||
| EPS Basic | -73.50% | 83.90% | |||
| Normalized Basic EPS | -73.48% | 70.30% | |||
| EPS Diluted | -73.50% | 83.90% | |||
| Normalized Diluted EPS | -73.48% | 70.30% | |||
| Average Basic Shares Outstanding | 6.80% | 6.63% | |||
| Average Diluted Shares Outstanding | 6.80% | 6.63% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||